We are proud to have advised long-standing client Brandon Capital on the establishment and final close of Brandon BioCatalyst 6 (BB6) – a $439 million life sciences fund supporting breakthrough biotech, therapeutics and medical manufacturing ventures. This landmark fund continues our partnership with Brandon Capital across multiple fund cycles as they transform cutting-edge research into globally relevant health solutions.
We advised on all aspects of BB6’s formation, including:
structuring the fund: four parallel trusts, including a novel debt arrangement to accommodate the National Reconstruction Fund Corporation (NRFC)
negotiating investments with a variety of superfund, corporate and government investors
coordinating each closing: from subscription deed execution to investor closing packs
establishing co-investment arrangements for selected investors.
This is Brandon Capital’s largest fund to date and one of the most significant raises in Australia’s venture capital and biomedical ecosystem. It also builds on our experience advising on complex fundraisings involving NRF participation, drawing on deep expertise in government-aligned investment structures.
The G+T team was led by Partner Deborah Johns, with support from Partners Julian Chen and Robert Trowbridge, and lawyers Matthew Charman, Jeremy Tjeuw, Nina Mao and Kelly Cai.
